Supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin.

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

“…23 The PEGmodified DOX tends to aggregate on the skin, which means that a small portion of the drug exudates through the capillaries of the hands and feet, resulting in HFS characterized by numbness, paresthesia, skin swelling or erythema, scaling, chapping, and induration blisters. 24 Half of the gynecologic oncology patients who received PLD at 40 mg/m 2 for a maximum of six cycles had HFS. 25 The HFS is partly caused by extravasation of the liposomes due to long circulation time.…”

Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis

“…In total, 238 articles were identified from the 3 databases (PubMed, EMBASE and CENTRAL) and by hand‐searching relevant bibliographies. We excluded 42 duplicates and 181 articles that did not satisfy the selection criteria, and then reviewed the remaining 15 studies . After excluding six studies for irrelevancy ( n = 3), insufficient data ( n = 1), and identical study populations ( n = 2), we were left with nine studies, which were included in the final analysis .…”

“…We excluded 42 duplicates and 181 articles that did not satisfy the selection criteria, and then reviewed the remaining 15 studies. 5,[11][12][13][14][15][16][17][18][19][20][21][22][23][24] After excluding six studies for irrelevancy (n = 3), 11,18,22 insufficient data (n = 1), 12 and identical study populations (n = 2), 15,17 we were left with nine studies, which were included in the final analysis. 5,13,14,16,[19][20][21]23,24 Of these, eight studies reported the preventive efficacy, 13,14,16,[19][20][21]23,24 three reported the treatment efficacy 5,14,19 and two studies reported both.…”